Does reduced CTLA-4 signaling prolong T-cell–driven inflammation during persistent antigen stimulation?

Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) is a fundamental negative regulator of the adaptive immune system, acting as a critical "brake" to prevent excessive T-cell activation. When this signaling pathway is compromised, the immune system loses its primary mechanism for resolving inflammation, particularly in environments where antigen stimulation remains persistent.

Mechanistic basis of T-cell inhibition

CTLA-4 dampens immune responses through high-affinity competitive binding and direct intracellular signaling.

• Ligand Sequestration: CTLA-4 has a significantly higher affinity for B7-1 (CD80) and B7-2 (CD86) ligands than the stimulatory receptor CD28. By sequestering these ligands, CTLA-4 prevents the essential co-stimulatory signal required for T-cell proliferation and survival.
• Trans-endocytosis: CTLA-4 actively removes B7 ligands from the surface of antigen-presenting cells (APCs) via trans-endocytosis, leading to their degradation and permanently reducing the APC's stimulatory capacity.
• Intracellular Signaling: The cytoplasmic tail of CTLA-4 recruits phosphatases (such as PP2A and SHP-2) that dephosphorylate key signaling molecules like ZAP-70 and Akt, directly inhibiting cytokine production (IL-2, IFN-γ) and inducing cell-cycle arrest.

Consequences of reduced signaling

When CTLA-4 signaling is reduced, the inhibitory threshold for T-cell activation is significantly lowered, leading to unchecked effector expansion.

• Chronic Antigen Stimulation: In scenarios of persistent antigen exposure (such as chronic infection or autoimmunity), the immune system requires heightened CTLA-4 expression to maintain homeostasis. Reduced signaling in these contexts prevents the necessary dampening of the immune response, resulting in prolonged, T-cell-driven inflammation.
• Genetic Modulation: Variants such as the rs3087243 (CT60) polymorphism influence this process by affecting CTLA-4 mRNA stability. Individuals with lower-expression genotypes (e.g., the A allele) demonstrate a diminished capacity to resolve inflammation compared to those with higher expression levels.
• Systemic Dysregulation: The clinical significance of this pathway is highlighted by CTLA-4 haploinsufficiency in humans, which results in severe autoimmune syndromes, massive memory T-cell expansion, and systemic multi-organ inflammation.

Bottom line

CTLA-4 is essential for dampening T-cell responses; a reduction in its signaling—whether through genetic variation or disease—impairs the immune system's ability to resolve inflammation, leading to prolonged and potentially damaging T-cell activity during persistent antigen stimulation.